In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections

Diagnostic Microbiology and Infectious Disease

Volumn 66, Issue 4, 2010, Pages 407-418

  Petersen, Peter J ^a   Ruzin, Alexey ^a   Tuckman, Margareta ^a   Jones, C Hal ^a  

^a WYETH RESEARCH   (United States)

Author keywords

Clinical isolates; Diabetic foot infection; In vitro susceptibility; MIC; Tigecycline

Indexed keywords

CEFOXITIN; CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; IMIPENEM; LINEZOLID; MINOCYCLINE; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACINETOBACTER LWOFFII; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEROIDES FRAGILIS; CITROBACTER FREUNDII; CITROBACTER KOSERI; CLOSTRIDIUM PERFRINGENS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CORYNEBACTERIUM; DIABETIC FOOT; DRUG EFFICACY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FINEGOLDIA MAGNA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PEPTONIPHILUS ASACCHAROLYTICUS; PEPTOSTREPTOCOCCUS; PREVOTELLA; PREVOTELLA BIVIA; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROTEUS VULGARIS; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; SERRATIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STAPHYLOCOCCUS HOMINIS; STAPHYLOCOCCUS LUGDUNENSIS; STAPHYLOCOCCUS SIMULANS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS DYSGALACTIAE; STREPTOCOCCUS MITIS; STREPTOCOCCUS ORALIS; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DIABETIC FOOT; DOUBLE-BLIND METHOD; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; WOUND INFECTION;

EID: 77649284813     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.11.009     Document Type: Article

References (33)

1. Babinchak T., et al. The efficacy and safety of tigecycline in the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41 Suppl. 5 (2005) S354-S367
2. Bradford P.A., et al. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials for complicated skin and skin structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. 41 Suppl. 5 (2005) S315-S332
3. Bradford P.A., et al. In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community acquired pneumonia. Clin. Microbiol. Infect. 14 (2008) 882-886
4. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests; approved standard-ninth edition, M02-A9 Vol. 26 (2006), CLSI, Wayne (PA)
5. Clinical and Laboratory Standards Institute (CLSI). Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard-seventh edition, M11-A7 Vol. 27 (2007), CLSI, Wayne (PA)
6. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 19th informational supplement (M100-S19) Vol. 29 (2009), CLSI, Wayne (PA)
7. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard-eighth edition, M07-A8 Vol. 29 (2009), CLSI, Wayne (PA)
8. Dean C.R., et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother. 47 (2003) 972-978
9. Dukart G., et al. Integrated results of 2 phase 3 studies comparing tigecycline (TGC) with levofloxacin (LEV) in patients (Pts) with community-acquired pneumonia (CAP). Abstr. L-1450. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006), American Society for Microbiology, San Francisco
10. Edlund C., and Nord C.E. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin. Microbiol. Infect. 6 (2000) 158-163
11. Ellis-Grosse E., et al. The efficacy and safety of tigecycline in the treatment of skin and skin structure infections: results of two double-blind phase 3 comparison studies with vancomycin/aztreonam. Clin. Infect. Dis. 41 Suppl. 5 (2005) S341-S353
12. Fritsche T.R., et al. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn. Microbiol. Infect. Dis. 52 (2005) 195-201
13. Jacobus N.V., et al. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob. Agents Chemother. 48 (2004) 1034-1036
14. Jones C., and Petersen P. Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic. Drugs Today 41 (2005) 637-659
15. Jones C.H., et al. Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections. Antimicrob. Agents Chemother. 50 (2006) 505-510
16. Jones C.H., et al. Genetic determinants of tetracycline resistance and their effect on tetracycline and glycylcycline antibiotics. Anti-Infect. Agents Med. Chem. 7 (2008) 84-96
17. Jones C.H., et al. Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. Antimicrob. Agents Chemother. 53 (2009) 465-475
18. Kenny G.E., and Cartwright F.D. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines and quinolones. Antimicrob. Agents Chemother. 45 (2001) 2604-2608
19. Lipsky B.A., et al. Diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 39 (2004) 885-910
20. Olson M.W., et al. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob. Agents Chemother. 50 (2006) 2156-2166
21. Petersen P.J., and Bradford P.A. Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob. Agents Chemother. 49 (2005) 3910-3918
22. Petersen P.J., et al. In vitro and In vivo antimicrobial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43 (1999) 738-744
23. Poole K. Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother. 56 (2005) 20-51
24. Reinert R.R., et al. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J. Antimicrob. Chemother. 60 (2007) 1018-1029
25. Roblin P.M., and Hammerschlag M.R. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int. J. Antimicrob. Agents 16 (2000) 61-63
26. Ruzin A., et al. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 49 (2005) 1017-1022
27. Sader H.S., et al. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis. 52 (2005) 181-186
28. Sotto A., et al. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers. Pathol. Biol. (Paris) 55 (2007) 398-406
29. Sum P.E., and Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. 9 (1999) 1459-1462
30. Tentolouris N., et al. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin. Microbiol. Infect. 12 (2006) 186-189
31. Tuckman M., et al. Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline. Antimicrob. Agents Chemother. 51 (2007) 3205-3211
32. Visalli M.A., et al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob. Agents Chemother. 47 (2003) 665-669
33. Wyeth Pharmaceuticals. Tygacil™ [package insert] (2005), Wyeth Pharmaceuticals Inc, Collegeville (PA) Vol. Accessed May 15, 2009